Multiple other strategies to enhance CAR-T cell expansion and persistence are being devised including overexpression of certain genes such as c-jun (59), CRISPR knockouts, TET2 gene disruption (105), enzyme overexpression to metabolically engineer against the tumor microenvironment (106), and expression of erythropoietin receptor in CAR constructs with the ability to expand in-vivo with erythropoietin. Here, EPO is linked to neoplasm.